<DOC>
	<DOCNO>NCT02101983</DOCNO>
	<brief_summary>High-dose cytarabine ( HiDAC ) consider standard chemotherapy treatment patient acute myeloid leukemia . However , patient receive therapy require admitted hospital treatment course . The purpose study compare safety cost high-dose cytarabine treatment give in-patient set versus out-patient setting .</brief_summary>
	<brief_title>Pilot Study Feasibility Outpatient Daily High Dose Cytarabine Consolidation Therapy Older Patients With Acute Myeloid Leukemia ( AML )</brief_title>
	<detailed_description>The primary objective study : • To determine incidence grade 3 5 non-hematologic toxicity high-dose cytarabine ( HiDAC ) AML consolidation administer outpatient setting . The secondary objective study : - To determine cost effectiveness outpatient HiDAC consolidation versus standard care inpatient HiDAC consolidation . - Evaluate patient quality life ( QOL ) outpatient regimen comparison standard inpatient regimen .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>Inclusion Criteria Outpatient Administration HiDAC Unequivocal diagnosis AML ( &gt; 20 % blast bone marrow base WHO classification ) , exclude M3 ( acute promyelocytic leukemia ) . Documented complete remission ( CR ) follow induction chemotherapy define ( 18 ) : Bone marrow &lt; 5 % blast ; absence blast Auer rod Absolute neutrophil count &gt; 1000/mcL Platelets &gt; 100,000/mcL Independence red cell transfusion Absence extramedullary disease Age ≥ 55 year . Relapsed AML patient eligible long meet inclusion exclusion criterion . Good performance status ( ECOG 02 ) , see appendix 15.3 . Adequate renal hepatic function ( Cr ≤ 1.2 , alkaline phosphatase &lt; 3.0 x upper limit normal , total bilirubin &lt; 1.5 x upper limit normal unless history Gilbert 's disease ) . Inclusion Criteria Quality Life Comparison Group All patient decline participate outpatient eligible participation outpatient portion study approach participate QOL comparison . Age ≥ 18 year Exclusion Criteria All Patients Active , uncontrolled viral , bacterial , fungal infection . Documented CNS leukemia . If unable reliable cerebellar examination monitoring neurotoxicity . History prior autologous allogeneic bone marrow/stem cell transplant . New York Heart Association class III/IV congestive heart failure , see appendix 15.4 , active ischemic heart disease . Pregnant lactate woman ( woman men childbearing age use effective contraception ) . Concomitant active malignancy require treatment cytotoxic chemotherapy radiation therapy . ( Ongoing hormonal therapy treatment malignancy would exclude patient trial . ) Time period great 10 week initiation induction chemotherapy day 1 first cycle consolidation chemotherapy . Patients seropositive infection Human Immunodeficiency Virus ( HIV ) exclude due potential serious infectious complication associate Tcell suppressive therapy patient .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Acute myeloid leukemia</keyword>
	<keyword>outpatient consolidation treatment</keyword>
</DOC>